The global myelodysplastic syndrome (MDS) treatment market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are driving the market growth include a rise in public awareness about myelodysplastic syndromes and their early diagnosis and the availability of new treatment options for MDS. Moreover, early diagnosis of MDS is important, as it significantly increases the quality of life in patients, reducing the chances of recurrent blood transfusion. Increasing regulatory approvals is another factor that is anticipated to fuel the market during the forecast period. For instance, in November 2018, Lupin obtained the US FDA approval of its Decitabine for Injection, 50 mg/vial, single-dose vial, a generic version of Otsuka Pharmaceutical Co. Ltd.'s Dacogen for Injection, 50 mg/vial, single-dose vial. Lupin’s generic version is indicated for the treatment of patients with myelodysplastic syndromes (MDS), which incorporates previously treated and untreated, de novo, as well as secondary MDS of all French-American-British subtypes.

Several Drug manufacturing companies and government organizations are focusing more on spreading awareness about the disease by providing funding and conducting awareness programs. For instance, in October 2018, Grupo Biotoscana, a Latin American biopharmaceutical company conducted a campaign for Myelodysplastic Syndrome World Awareness Day, which is celebrated on 25th October. GBT Grupo Biotoscana launched a campaign to raise awareness and educate about the disease throughout the month. Moreover, increasing launch and approval of Azacitidine in some regions is expected to drive the market growth during the forecast period. For instance, in February 2018, BeiGene, Ltd. introduced the commercial availability of VIDAZ (azacitidine for injection) in China. VIDAZA is accredited in China for patients with intermediate-2/excessive-chance myelodysplastic syndrome (MDS), acute myeloid leukaemia (AML) with 20-30% bone marrow blasts, and chronic myelomonocytic leukaemia. It is marketed in China by BeiGene under an exclusive license from Celgene Corp.

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Celgene Corp., Otsuka Pharmaceutical Co., Ltd., and Dr. Reddy's Laboratories Ltd., among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Myelodysplastic Syndrome (MDS) Treatment Market Report by Segment

By Drug

• Azacitidine

• Lenalidomide

• Decitabine

• Deferasirox

Global Myelodysplastic Syndrome (MDS) Treatment Market by Region